EP2521735A2 - Diabody bivalent humain recombinant contre le virus de la rage et utilisation de celui-ci - Google Patents
Diabody bivalent humain recombinant contre le virus de la rage et utilisation de celui-ciInfo
- Publication number
- EP2521735A2 EP2521735A2 EP11708575.3A EP11708575A EP2521735A2 EP 2521735 A2 EP2521735 A2 EP 2521735A2 EP 11708575 A EP11708575 A EP 11708575A EP 2521735 A2 EP2521735 A2 EP 2521735A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- diabody
- seq
- rabies virus
- recombinant
- recombinant human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241000711798 Rabies lyssavirus Species 0.000 title claims abstract description 54
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 29
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 29
- 239000002157 polynucleotide Substances 0.000 claims abstract description 29
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 claims abstract description 27
- 229960005486 vaccine Drugs 0.000 claims abstract description 21
- 206010037742 Rabies Diseases 0.000 claims description 35
- 210000004027 cell Anatomy 0.000 claims description 27
- 241000700605 Viruses Species 0.000 claims description 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 239000013598 vector Substances 0.000 claims description 15
- 241000588724 Escherichia coli Species 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 108020004511 Recombinant DNA Proteins 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 241000295638 Australian bat lyssavirus Species 0.000 claims description 2
- 241001520695 Duvenhage lyssavirus Species 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 16
- 230000003472 neutralizing effect Effects 0.000 abstract description 3
- 238000002965 ELISA Methods 0.000 description 43
- 239000000427 antigen Substances 0.000 description 29
- 102000036639 antigens Human genes 0.000 description 29
- 108091007433 antigens Proteins 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 230000036515 potency Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 239000012634 fragment Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 12
- 239000000523 sample Substances 0.000 description 11
- 230000027455 binding Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 238000003312 immunocapture Methods 0.000 description 8
- 239000006166 lysate Substances 0.000 description 8
- 238000011002 quantification Methods 0.000 description 8
- 229960003127 rabies vaccine Drugs 0.000 description 8
- 108090000288 Glycoproteins Proteins 0.000 description 7
- 102000003886 Glycoproteins Human genes 0.000 description 7
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 238000006386 neutralization reaction Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 229960000074 biopharmaceutical Drugs 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 239000003593 chromogenic compound Substances 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 108010087302 Viral Structural Proteins Proteins 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- KJDSORYAHBAGPP-UHFFFAOYSA-N 4-(3,4-diaminophenyl)benzene-1,2-diamine;hydron;tetrachloride Chemical compound Cl.Cl.Cl.Cl.C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 KJDSORYAHBAGPP-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000711828 Lyssavirus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101900236200 Rabies virus Nucleoprotein Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 230000010530 Virus Neutralization Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 238000011005 laboratory method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000012369 In process control Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010033737 Pokeweed Mitogens Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 208000010726 hind limb paralysis Diseases 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000010965 in-process control Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
Definitions
- the present invention is in the field of immunology in particular production of recombinant : antibody fragments.
- the present invention specifically relates to production of recombinant human bivalent diabody protein against rabies virus.
- Rabies is an invariably fatal viral infection of the nervous system of warm blooded animals including humans. It is transmitted by the bite of an infected animal, usually from a dog (Jackson, A.C., (2003). Rabies virus infection: an update. Journal for Neurovirology, 9; 253-258). It is estimated that every year 2.5-3 million people in India require post-exposure vaccination (Hemachudha T, Phuapradit P. (1997). Rabies. Current Opinion in Neurology. 10; 260-267). Potency determination of rabies vaccines involving the use of in vivo tests in mice (WHO, 1992) and in vitro methods based on estimation of rabies virus glycoprotein have been described (Perrin et al. (1990).
- the first object of the present invention is to provide recombinant human bivalent diabody protein capable of recognizing rabies virus glycoprotein.
- the second object of the present invention is to provide a method of production of the recombinant human bivalent diabody specific for rabies virus glycoprotein.
- the third object of the present invention is to develop an ELISA for the quantification of rabies viral glycoprotein.
- One aspect of the present invention provides a recombinant human bivalent diabody having amino acid sequence as set forth in SEQ ID NO: 26, wherein the diabody binds to rabies virus and neutralizes the virus.
- Another aspect of the present invention provides a polynucleotide encoding recombinant human bivalent diabody, wherein nucleotide sequence of the polynucleotide is as set forth in SEQ ID NO: 25.
- Figure 1 shows electrophoretic analysis of PCR amplified variable heavy chain (A), variable light chain (B) and the assembled diabody product (C). These gene sequences were amplified from total RNA isolated from a hetero-hybridoma secreting a fully human monoclonal antibody; Lane: M-Molecular weight marker, VH-Variable heavy chain, VL-Variable light chain and D-Assembled diabody product.
- FIG. 2 shows SDS-PAGE analysis of purified bivalent diabody.
- the purified protein was detected by staining with Coomassie brilliant blue and was determined to be of 27 KDa by running along with protein molecular weight marker.
- Figure 3 shows western blot analysis of purified bivalent diabody fractions obtained after column chromatography. The blot was reacted with His probe specific for the Histidine tag of the bivalent diabody. A protein band of 27 kDa was detected.
- Lanes Lane 1 -5, fractions obtained from column chromatography purification of bivalent diabody; Lane M: Prestained molecular weight marker.
- Figure 4 illustrates an immuno- capture ELISA using the bivalent diabody.
- the test sample B containing M5B4 (anti-rabies murine monoclonal antibody), PV Ag (Pasteur virus antigen), D06 (bivalent diabody) and His-Probe.
- a and C are the negative control.
- A is without diabody and C is without the PV Ag.
- Figure 5 illustrates competitive ELISA using the bivalent diabody and the anti- rabies murine monoclonal antibody (M5B4).
- A contains PV Ag, E. coli Lysate, M5B4 (anti-rabies murine monoclonal antibody), and anti mouse HRP.
- B is without E. coli lysate.
- Figure 6 illustrates the vector map showing the cloned bivalent diabody fragment.
- Figure 7 shows the SDS-PAGE analysis of human monoclonal antibody secreted by heterohybridoma clones after affinity purification on protein A sepharose column. The antibodies are run along with BSA as standard.
- Figure 8 illustrates the schematic representation of the constructed vector containing diabody gene cloned between EcoRl and Noil sites of pET 28a bacterial expression vector.
- Figure 9 shows the specific binding of diabody to Rabies viral structural proteins transferred onto PVDF membrane by Immunoblot assay
- Figure 10 shows the binding specificity of diabody by immunoreactivity assay
- diabody used herein refers to an engineered antibody and/or antibody fragments that are bivalent, monospecific or bispecific molecules generated by dimerization of two variable heavy-variable light fragments.
- bivalent used herein refers to an antibody and/or antibody fragment having two antigen binding sites capable of binding to two molecules of same or different antigens with great avidity.
- the present invention provides a method for production of recombinant bivalent diabody against rabies virus.
- the present invention further provides bivalent diabody rabies, composition comprising the bivalent diabody fragment and uses thereof.
- the bivalent diabody fragment disclosed in the present invention recognizes rabies virus glycoprotein.
- the bivalent diabody were constructed using gene sequences of a fully human monoclonal antibody secreted by a human X mouse heterohybridoma.
- the present invention relates to the development of a bivalent diabody fragment constructed from a heterohybridoma (human X mouse) and having two antigen binding sites that is reactive against the glycoprotein of rabies virus and its use in the development of ELISA for the quantitation of rabies virus glycoprotein.
- the present invention provides a method for production of recombinant bivalent diabody fragment construction from heterohybridoma and their use in the quantification of rabies glycoprotein.
- Heterohybridoma was generated by immortalizing immune human B cells mediated by a human X mouse heteromyeloma (Champion et al. (2000).
- the recombinant bivalent diabody was constructed from heterohybridoma and this recombinant diabody was used in the development of an ELISA for the quantitation of rabies virus glycoprotein in the vaccine manufacture.
- DNA encoding variable domains of heavy and light chains were amplified separately by PCR and assembled into diabody with a short linker by splicing overlap extension polymerase chain reaction (SOE PCR).
- SOE PCR splicing overlap extension polymerase chain reaction
- Sequence of the recombinant diabody was verified and cloned into pET 28a vector and transformed into E. coli strain (BL21 -DE3) cells for soluble expression of diabody.
- the soluble diabody protein was purified using immobilised metal affinity chromatography method. The purified protein was checked for their antigen binding activity using the rabies virus glycoprotein and was found to be nearly identical to the parental antibody.
- the present invention further provides use of the recombinant diabody disclosed in the present invention for detection and quantification of rabies virus glycoprotein in the vaccine manufacture.
- the recombinant human diabody which was constructed from heterohybridoma is one of the smallest recombinant bispecific antibodies consisting of two antigen binding sites devoid of constant regions and therefore provides high binding avidity and specificity to the target antigens similar to the parent antibody.
- the recombinant bivalent diabody as disclosed in the present invention can be over expressed in bacteria and produced in large quantities at low cost to guarantee the supply of a consistent and well-characterized specific reagent to quantify rabies virus glycoprotein which can than be used to evaluate vaccine potency.
- a recombinant human bivalent diabody having amino acid sequence as set forth in SEQ ID NO: 26, wherein the diabody binds to rabies virus and neutralizes the virus.
- Another embodiment of the present invention provides a recombinant human bivalent diabody having amino acid sequence as set forth in SEQ ID NO: 26, wherein the diabody binds to rabies virus and neutralizes the virus, wherein the rabies virus is selected from genotype (GT) 1 (GT1) (PV, Flury LEP, SAD, CVS- 1 1), GT4 ⁇ Duvenhage virus (DUV) ⁇ and GT7 ⁇ Zealandn bat lyssavirus (ABLV) ⁇ .
- Another embodiment of the present invention provides a recombinant human bivalent diabody having amino acid sequence as set forth in SEQ ID NO: 26, wherein the diabody binds to rabies virus and neutralizes the virus, wherein the diabody is a monoclonal antibody.
- Another embodiment of the present invention provides a recombinant human bivalent diabody having amino acid sequence as set forth in SEQ ID NO: 26, wherein the diabody binds to rabies virus and neutralizes the virus, wherein the diabody is a fully human monoclonal antibody.
- Another embodiment of the present invention provides a recombinant human bivalent diabody having amino acid sequence as set forth in SEQ ID NO: 26, wherein the diabody binds to rabies virus and neutralizes the virus, wherein the diabody is monospecifc monoclonal antibody.
- Another embodiment of the present invention provides a polynucleotide encoding recombinant human bivalent diabody, wherein the nucleotide sequence of the polynucleotide is as set forth in SEQ ID NO: 25.
- Another embodiment of the present invention provides a polynucleotide encoding recombinant human bivalent diabody, wherein nucleotide sequence of the polynucleotide is as set forth in SEQ ID NO: 25, wherein the polynucleotide encodes recombinant human bivalent diabody having amino acid sequence as set forth in SEQ ID NO: 26.
- Yet another embodiment of the present invention provides a recombinant DNA expression cassette comprising the polynucleotide encoding recombinant human bivalent diabody, wherein the nucleotide sequence of the polynucleotide is as set forth in SEQ ID NO: 25, wherein the polynucleotide is operably linked to a promoter.
- the present invention provides a recombinant vector comprising the recombinant DNA expression cassette comprising the polynucleotide encoding recombinant human bivalent diabody, wherein the nucleotide sequence of the polynucleotide is as set forth in SEQ ID NO: 25, wherein the polynucleotide is operably linked to a promoter.
- Yet another embodiment of the present invention provides a recombinant host cell comprising the DNA expression cassette comprising the polynucleotide encoding recombinant human bivalent diabody, wherein the nucleotide sequence of the polynucleotide is as set forth in SEQ ID NO: 25.
- Yet another embodiment of the present invention provides host cell selected from a group consisting of E. coli, yeast and CHO cells.
- the present invention further provides a composition comprising a recombinant human bivalent diabody having amino acid sequence as set forth in SEQ ID NO: 26, wherein the diabody binds to rabies virus and neutralizes the virus.
- the present invention further provides a composition comprising a recombinant human bivalent diabody having amino acid sequence as set forth in SEQ ID NO: 26 and pharmaceutically acceptable carrier, wherein the diabody binds to rabies virus and neutralizes the virus.
- the present invention also provides a vaccine composition
- a vaccine composition comprising a recombinant human bivalent diabody having amino acid sequence as set forth in SEQ ID NO: 26 or the polynucleotide sequence as set forth in SEQ ID NO: 25.
- the present invention also provides a vaccine composition comprising a recombinant human bivalent diabody having amino acid sequence as set forth in SEQ ID NO: 26.
- Another embodiment of the present invention provides a therapeutic biological composition
- a therapeutic biological composition comprising the recombinant human bivalent diabody having amino acid sequence as set forth in SEQ ID NO: 26 or the polynucleotide having the nucleotide sequence as set forth in SEQ ID NO: 25.
- kits for estimation of rabies virus glycoprotein comprising a recombinant human bivalent diabody having amino acid sequence as set forth in SEQ ID NO: 26.
- a method for treating rabies virus associated disease and/or disorders is also provided herein, wherein the method comprises administering an effective amount of the recombinant human bivalent diabody having amino acid sequence as set forth in SEQ ID NO: 26 to the subject in need thereof.
- the present invention also provides use of the recombinant human bivalent diabody having amino acid sequence as set forth in SEQ ID NO: 26 to the subject in need thereof for the preparation of medicament for the treatment of rabies associated disease or disorders.
- Still another embodiment of the present invention provides a recombinant human bivalent diabody having amino acid sequence as set forth in SEQ ID NO: 26, wherein the diabody is produced in bacteria.
- Another embodiment of the present invention provides a recombinant human bivalent diabody having amino acid sequence as set forth in SEQ ID NO: 26, wherein the diabody binds to rabies virus glycoprotein.
- Another embodiment of the present invention provides a recombinant human bivalent diabody having amino acid sequence as set forth in SEQ ID NO: 26, wherein the diabody binds to rabies virus glycoprotein G.
- Still another embodiment of the present invention provides a test kit for estimation of rabies virus glycoprotein, wherein the kit comprises a recombinant human bivalent diabody encoded by the polynucleotide as set forth in SEQ ID NO: 25.
- Various vaccine batches tested by diabody based IC-ELISA showed a good correlation with the NIH mouse potency studies as seen with MAb-M5B4 based IC-ELISA (Nagarajan et al 2006, WHO 1988).
- Quantification of RV GP using diabody based IC-ELISA provides exact information of the natively folded RV GP antigen in vaccine preparations and in-process control samples which enables reliable estimation of RV GP.
- diabody based IC-ELISA could replace the MAb based IC-ELISA due to better reagent stability and ease of production.
- Rabies Virus Strain used in the present invention is the Pasteur virus (PV) strain described in literature.
- Human X mouse heterohybridoma was generated by fusing immune human B cells with human X mouse heteromyeloma (Champion et al. (2000); The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure. Journal of Immunological Methods 235(1-2): 81 -90).
- the heterohybridomas were developed by fusing primary immune peripheral blood B-cells and a heteromyeloma cell line, K6H6/B5 (Carroll et al. (1986); Mouse x human heterohybridomas as fusion partners with human B cell tumors.
- the K6H6/B5 cell line was chosen because it has been successfully used to clone human anti-viral antibodies (Siemoneit et al. (1994). Isolation and epitope characterization of human monoclonal antibodies to hepatitis C virus core antigen. Hybridoma. 13(1): 9-13; Funaro et al. (1999). Identification of a 220-kDa membrane tumor-associated antigen by human anti-UK1 14 monoclonal antibodies selected from the immunoglobulin repertoire of a cancer patient. Experimental Cell Research 247(2): 441 -450).
- the immune B cells isolated from a human subject vaccinated several times with the human rabies vaccine PVRV (Abhayrab, Human Biologicals Institute, Udhagamandalam) which incorporates PV strain of rabies virus which is known to provide broad coverage against street rabies virus (SRV) isolates (Badrane H, Bahloul C, Perrin P and Tordo N (2001). Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity, Journal of Virology 75; 3268-3276) were stimulated with pokeweed mitogen, before fusion. Using the hybridoma method, 8 new human IgG antibodies (huMabs) that bind the rabies virus glycoprotein were cloned.
- PVRV Human Biologicals Institute, Udhagamandalam
- the 8 new human IgG antibodies were characterized to determine their isotype, specificity and cross-reactivity.
- Each of the huMabs was of gamma 1 ( ⁇ ) heavy chain and lambda ( ⁇ ) light chain isotype (Table 1 ).
- Their specificity to RV was demonstrated by a Cell-ELISA using unfixed mock and RV infected cultured cells. All the huMabs showed reactivity to all the fixed RVs except the BHK-21 -adapted CVS strain (CVS- RV). None of the huMabs showed any reactivity to host cell protein (Table 2).
- the huMabs bound specifically to native form of whole virus antigens as well as purified rabies virus glycoprotein and did not react with rabies virus nucleoprotein as evident from the results of Indirect ELISA (Table 1 ).
- the huMabs recognized antigenic site III of rabies virus glycoprotein as determined by a competitive ELISA using a mouse Mab (Dl ) against antigenic site III as described elsewhere (Nagarajan et al. (2006), A simple immuno-capture ELISA to estimate rabies viral glycoprotein antigen in vaccine manufacture, Biologicals. 34: 21 -27).
- the huMabs have been tested for their ability to neutralize various street and fixed RVs both in vitro and in vivo.
- mouse neutralization test MNT
- the huMabs neutralized all the four Indian street rabies viruses (SRVs) of dog origin (108, 141 , 142, & 129) (Table 3).
- All the 8 huMabs neutralized four fixed RV strains viz. Pasteur Virus (PV), Flury LEP, SAD and CVS- 1 1 ) while none of the huMabs neutralized BHK-21 adapted CVS RV when tested by rapid fluorescent focus inhibition test (RFFIT) (Table 4).
- PV Pasteur Virus
- RFFIT rapid fluorescent focus inhibition test
- the clones were screened for the specific human Mab secretion by indirect ELISA employing purified inactivated rabies virus antigen (PV strain).
- the human monoclonal antibody (Mabs) secreted by heterohybridoma clones have been affinity purified on protein A sepharose column.
- the purified antibody was checked on gel ( Figure 7).
- Lane 1 shows BSA as standard whose molecular weight is 66 KDa.
- Lane 2-5 shows the purified R16E5 Human monoclonal antibody of molecular weight 160 KDa.
- the main criterion for selecting four out of 8 clones was rabies virus neutralization spectrum as determined by RFFIT.
- the huMabs were screened for the rabies whole virus antigen specific activity by indirect ELISA.
- An ELISA plate was coated with zonal purified rabies whole virus antigen (1 : 100 dilution) in carbonate buffer overnight at 2-8°C. The plate was washed thrice with PBST and the unsaturated sites were blocked with 1% bovine gelatin.
- the antigen coated on the solid phase was probed with huMabs and the presence of immune complex detected with goat anti-human IgG-peroxidase conjugate followed by the addition of TMB chromogenic substrate
- the plate was read at 450 nm wavelength after stopping the colour reaction with 1.25M H 2 S0 . Growth medium and immune mouse serum were used as negative and positive controls respectively. The results are furnished in Table 1. It is clear from the results that the huMabs exhibited rabies whole virus antigen specific activity.
- the huMabs were screened for the rabies virus specific activity by cell ELISA using rabies virus (PV strain) infected and mock infected VERO monolayer cell culture. The unsaturated sites were blocked using 1% bovine gelatin after fixing the cell sheet with 70% cold acetone. The plate was washed thrice with PBST and the fixed cell sheet was then was probed with huMabs. The presence of immune complex was detected with goat anti-human IgG-peroxidase conjugate followed by the addition of TMB chromogenic substrate. Growth medium and immune mouse serum were used as negative and positive controls respectively. The results are furnished in Table 2. It is clear from the results that the huMabs exhibited rabies virus specific activity essentially free from any cross-reactivity with the host cell proteins.
- the huMabs were screened for their ability to neutralize fixed strain of rabies virus by RFFIT.
- the huMabs were heat inactivated before setting up a neutralization reaction with 50 FFD 5 o of rabies virus (CVS-1 1 strain) by incubating at 37°C for 90 minutes.
- the presence of unneutralized virus in the mixture after incubation was determined by seeding it along with an indicator cell line (MNA cell line) and incubated for 20 hours.
- MNA cell line indicator cell line
- the cell sheet was fixed with 70% cold acetone and probed with rabbit anti rabies virus nucleocapsid IgG-FITC conjugate to demonstrate the presence of rabies virus.
- Human serum of known titer sourced from NIBSC, UK was used as the internal reference standard. The results are furnished in Table 4. It is clear from the results that the huMabs potentially exhibited rabies virus neutralizing activity.
- the huMabs were screened for their ability to neutralize fixed and street rabies viruses by MNT.
- the huMabs were heat inactivated before setting up a neutralization reaction with 50 LD50 of either fixed or street rabies virus by incubating at 37°C for 90 minutes.
- the presence of unneutralized virus in the mixture after incubation was determined by intracerebral ly inoculating weaned mice and observed daily for the signs of rabies such as typical hind limb paralysis for a period of 21 days.
- HRIG of known titer obtained from a commercial vendor was used as the internal reference standard. The results are furnished in table 3. It is clear from the results that the huMabs potentially exhibited the ability to neutralize fixed and street rabies viruses.
- RNA was isolated from anti rabies heterohybridoma (R16E5) and DNA was synthesized by RT-PCR.
- the nucleotide sequence of the amplified c-DNA is as set forth in SEQ ID NO: 25.
- the RT-PCR amplified cDNA was used as template for amplification of variable domains of an antibody with universal primers having nucleotide sequence as set forth in SEQ ID NO: 1 to SEQ ID NO: 20).
- the amplified variable domains were assembled to form diabody by splicing by overlap extension PCR and cloned in TOPO vector for sequence verification ( Figure 1A, Figure IB and Figure 1C).
- HuVHla SEQ ID NO: 1
- HuVH3a SEQ ID NO: 3
- HuVH4a SEQ ID NO: 4
- HuVH5a SEQ ID NO: 5
- HuVH6a SEQ ID NO: 6
- HuJHl-2 SEQ ID NO: 7
- HuJH3 SEQ ID NO: 8
- HuJH4-5 SEQ ID NO: 9
- HuJH6 SEQ ID NO: J O
- HuLAMl SEQ ID NO: 1 1
- HuLAM2 SEQ ID NO: 12
- HuLAM3a SEQ ID NO: 13
- HuLAM3b SEQ ID NO: 14
- HuLAM4 SEQ ID NO: 15
- HuLAM5 SEQ ID NO: 16
- HuJLAMl SEQ ID NO: 18
- HuJLAM2-3 SEQ ID NO: 19
- HuJLA 4-5 SEQ ID NO: 20
- variable heavy chain (VH) and light chain (VL) were amplified from the cDNA using the universal human variable primers.
- Human variable heavy chain (HuVH) forward primers and human joining heavy chain (HuJH) reverse primers were used to amplify variable heavy chain.
- VH antibody variable heavy chain
- V L variable light chain
- the PCR reaction conditions are kept in the following order: 95°C x 5 minutes, 92 °C x 1 minute, 63 °C x 1 minute, 72 °C x 1 minute for 34 . cycles, and 72 °C x 10 minutes.
- PCR program was arranged in the following order: 95 °C x 5 minutes, 92 °C x 1 minute, 63 °C x 1 minute, 72 °C x 1 minute for 14 cycles, and 72 °C x 10 minutes.
- the PCR product obtained was used as a template and amplified with primers listed above as SEQ ID NO: 1 1 to SEQ ID NO: 17 as forward primer and SEQ ID NO: 7 to SEQ ID NO: 10 as reverse primer.
- the PCR conditions followed are: 95 °C x 5 minutes, 92 °C x 1 minute, 63 °C x 1 minute, 72 °C x 1 minute for 34 cycles, and 72 °C x 10 minutes.
- the resultant PCR product was amplified with the primers listed above as SEQ ID NO: 21 and SEQ ID NO: 22 to obtain the PCR product of 714 base pairs (SEQ ID NO: 25) for construction of diabody.
- the amplified variable heavy and light chains were joined together with the polypeptide linker using SOE and the resulted PCR product of 714 base pairs (SEQ ID NO: 25) was cloned into TOPO-TA vector. Positive clones which showed release of 714 base pairs (bps) product after enzymatic analysis of the plasmids were sequenced and blasted the sequence by using NCBI blast search showed the presence of 363 bps of variable heavy chain, 327 bps of variable light chain and 24 bps linker region which forms a diabody of 714 bps having the polynucleotide as set forth in SEQ ID NO: 25.
- the resultant PCR product of 714 base pairs (SEQ ID NO: 25) was further amplified using the primers as set forth in SEQ ID NO: 23 and SEQ ID NO: 24 to add the restriction site for cloning into pET vector.
- Primer 2 SEQ ID NO: 24
- the diabody fragment having polynucleotide as set forth in SEQ ID NO: 25 was cloned between EcoRl and Noil sites of pET 28a bacterial expression vector.
- the vector pET 28a and the insert referred to diabody of size 714 bps was digested with EcoRl and Noil, respectively by incubating at 37°C for 12 hours.
- the digested products was purified using the kit provided by QIAGEN and kept for various ratios of vector to insert (i.e., 1 :3 and 1 :6) blunt end ligation and incubated at 22°C for 2 hours.
- the ligated product was incubated for further 20 minutes at 65°C in order to inactive the enzyme.
- the pET 28a vectors carry an N-terminal His tag/thrombin/T7 Tag configuration plus an optimal C-terminal His tag sequence.
- T7 promotor and T7 terminator are situated used to sequence the single stranded insert DNA fragment of the diabody. The insert was verified by sequencing the clone from vector backbone using T7 promotor and T7 terminator primers. The obtained 714 base pairs sequence is as set forth in SEQ ID NO: 25.
- Overnight grown XL-Blue strain culture was sub-cultured and grown at 37°C, shaking until the OD of the culture reaches to 0.6 at 600nm.
- the culture was harvested by centrifuging at 5000 x rpm for 10 minutes at 4°C and resuspended in ice-cold O. lmM CaCl 2 and incubated overnight on the ice, before proceeding for transformation.
- the chemically competent XL-Blue cells were incubated with plasmid DNA for 30 minutes on ice.
- the cells were given heat shock at 42°C for 90 seconds and immediately placed in ice for 2 minutes before the media was added to cells.
- the cells were incubated for one hour at 37°C for recovery and plated on semi-solid media containing 50mg/ml of kanamycin.
- the plates were incubated for overnight and screened for positive clones by isolating the plasmids and subjected to digestion with EcoRl and No/I.
- the positive clones were sequence verified before the plasmid was transformed into BL-21 DE3 cells of E .coli for soluble expression of the antibody gene.
- the recombinant diabody fragment having polynucleotide sequence as set forth in SEQ ID NO: 25 was expressed in E. coli for production of recombinant human monoclonal diabody protein having polypeptide sequence as set forth in SEQ ID NO: 26. Further, the diabody protein was purified from the soluble fraction of the lysate using Immobilized Metal Affinity Chromatography (IMAC).
- IMAC Immobilized Metal Affinity Chromatography
- the purified recombinant human diabody protein was analyzed and a band of 27 KDa size was visualized on 12% reducing SDS-PAGE after staining with Coomassie brilliant blue ( Figure 2) and detected with His-Probe in western blotting ( Figure 3) Yield of the affinity purified protein was quantified using Bicinchoninic Acid kit and found to be on an average of 5mg/10L.
- Immuno capture ELISA was performed to check the binding affinity of the recombinant human bivalent diabody protein.
- a micro titer plate was coated with mouse monoclonal antibody (Mab) M5B4 (l OOng/well) in carbonate buffer by incubating over night at 4°C. The plate was washed thrice with PBST and the unbound sites in the wells were blocked with 1% bovine gelatin. Purified rabies virus glycoprotein (Pasteur virus strain) was added in different dilutions and allowed to react with M5B4. Diabody protein tagged with Histidine was added and allowed to react with captured antigen. The affinity binding of the diabody with rabies virus glycoprotein was detected by adding His-Probe and a chromogenic substrate TMB. The plate was read at 450nm after the reaction was stopped with 1.25M H 2 So 4 ( Figure 4) .
- IC-ELISA was performed to quantify the Rabies Virus Glyco Protein (RV GP) content in rabies vaccine formulations, according to the method described by Nagarajan et al. ⁇ Nagarajan, T., G. S. Reddy, B. Mohana Subramanian, S. Rajalakshmi, D.Thiagarajan, N. Tordo, C. Jallet, and V. A. Srinivasan. 2006. A simple immuno-capture ELISA to estimate rabies viral glycoprotein antigen in vaccine manufacture. Biologicals 34:21-27. ⁇ , with a few modifications wherein the diabody (450 ng/well) was used for detection.
- RV GP Rabies Virus Glyco Protein
- ELISA plate was coated with mouse monoclonal antibody (MAb) M5B4 overnight at 4°C and the un-reacted sites blocked with 1% bovine gelatin.
- the test vaccines and an internal reference standard (IRS) vaccine of known RV GP were subjected to 8 serial 2 fold dilutions in PBS-T.
- the RV GP trapped by MAb M5B4 was detected using the diabody followed by the addition of anti-1 His Probe.
- the plate was developed with TMB at room temperature for 10 minutes.
- the reaction was stopped by addition of 1.25M H2S04 and the absorbance was measured at 450 nm wave length using a micro titre plate reader (BIO-TEK, USA).
- the assay was performed in triplicate.
- the RV GP content was also estimated by MAb-M5B4 IC- ELISA previously described b Nagarajan et al. 2006, using reference standard vaccine.
- the RV GP content was estimated using the formula
- NIH potency test was carried out on the different rabies vaccine formulations in mice using standard procedures (Wilber, L. A., and M. F. A. Aubert. 1996. The NIH test for potency, p.360-368. In F. X. Meslin, M. M. Kaplan, and H. Koprowski (ed.), Laboratory techniques in rabies, 4th ed. WHO, Geneva, Switzerland.).
- PV GP was estimated in 65 batches of experimental human rabies vaccine preparations using the IC-ELISA and the estimates were compared to the NIH potency values of those respective batches.
- ANOVA with Regression Through the Origin (RTO) model was performed to compare the potency estimates derived by M5B4-D06 IC-ELSIA and MAb-M5B4 IC-ELISA previously described by Nagarajan et al., (2006).
- Regression analysis was performed using the data analysis program in Microsoft Excel 2003 to compare the potency estimates derived by M5B4D06 IC-ELSIA and MAb-M5B4 IC-1 ELISA with the NIH estimate.
- the adjusted R2 value obtained was 0.902 and equation for predicted potency values for M5B4-D06 based IC-ELISA and MAb-M5B4 IC-ELISA were 0.565 lx and 0.8044x respectively, where x is the estimate of RV GP by the IC-ELISA in ⁇ g ( Figure 1 1a and l i b).
- ANOVA results showed the estimates by the two methods compared differed highly significantly (PO.001 ) while the predicted potencies by the two test did not differ significantly (P>0.05).
- mice Mab The constant amount of mouse Mab (M5B4) was added to each well containing diabody and E.coli lysate and the plates were incubated at 37°C for 1 hour. The plate was washed with PBST as mentioned above. Goat anti-mouse IgG HRP conjugate with the working dilution of 1 :5000 (as recommended by the manufacturer) was added to each well and the plates were incubated further at 37°C for 1 hour. The plate was washed five times with PBST before chromogenic substrate TMB was added. TMB substrate was prepared by dissolving one TMB tablet and 3 ⁇ ) of 3 ⁇ 4(1 ⁇ 4 in citrate buffer and an aliquot of ⁇ ⁇ added to each well. The reaction was stopped by adding ⁇ ⁇ of ] .25 M H2SO4 to each well and plate was read at 450 nm ( Figure 5).
- CVS- 1 1 essentially as described by Smith et al. ( 1996).
- Table 3 Survivorship of Swiss albino mice subjected to mouse neutralization test b to demonstrate the ability of human monoclonal antibodies to neutralize various fixed and street rabies viruses in vivo
- mice Female Swiss albino mice (3-4 weeks old) were intracranialy inoculated with 30 ⁇ of (50 MlCLD 50 /30 ⁇ ) either rabies virus infected culture fluid or brain homogenates from naturally infected rabid stray dogs. The inoculated mice were observed daily for symptoms typical of rabies for 21 days. The results are expressed as per centage of mice that survived after 21 days of observation.
- Table 5 Neutralization of rabies-related viruses by anti-rabies virus human monoclonal antibodies
- VNA titer was determined by RFFIT at CDC, Atlanta, essentially as described by Smith et al. (1996).
- RFFIT rapid fluorescent focus inhibition test
- Partially purified buMAb preparation was used.
- SEQ ID NO: 26 Amino acid sequence of diabody fragment (238 a. a.)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN15CH2010 | 2010-01-04 | ||
PCT/IN2011/000001 WO2011080765A2 (fr) | 2010-01-04 | 2011-01-03 | Diabody bivalent humain recombinant contre le virus de la rage et utilisation de celui-ci |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2521735A2 true EP2521735A2 (fr) | 2012-11-14 |
Family
ID=44226923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11708575.3A Ceased EP2521735A2 (fr) | 2010-01-04 | 2011-01-03 | Diabody bivalent humain recombinant contre le virus de la rage et utilisation de celui-ci |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2521735A2 (fr) |
CN (1) | CN103596975A (fr) |
WO (1) | WO2011080765A2 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2014KN02831A (fr) * | 2012-05-24 | 2015-05-08 | Mountgate Group Ltd | |
US20150276738A1 (en) * | 2012-10-12 | 2015-10-01 | The USA, as represented by the Secretary, Dept. of Health & Human Service,Centers for Disease Contro | Assay for analyses of rabies virus glycoprotein |
BR122020023406B1 (pt) | 2014-11-18 | 2023-10-31 | Institut Pasteur | Anticorpos que neutralizam de modo potente vírus da raiva e outros lissavírus, moléculas de ácido nucleico, vetor, célula isolada, composição farmacêutica, usos dos mesmos, e kit de partes |
RU2764740C1 (ru) * | 2018-08-09 | 2022-01-20 | Бейцзин Уиздомаб Байотекнолоджи Ко., Лтд | Биспецифическое антитело против вируса бешенства и его применение |
CN111999497B (zh) * | 2020-08-24 | 2023-08-08 | 中牧实业股份有限公司 | 检测狂犬病毒糖蛋白抗原的酶联免疫试剂盒及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ550366A (en) * | 2004-05-27 | 2009-11-27 | Crucell Holland Bv | Binding molecules capable of neutralizing rabies virus and uses thereof |
-
2011
- 2011-01-03 EP EP11708575.3A patent/EP2521735A2/fr not_active Ceased
- 2011-01-03 WO PCT/IN2011/000001 patent/WO2011080765A2/fr active Application Filing
- 2011-01-03 CN CN201180012154.7A patent/CN103596975A/zh active Pending
Non-Patent Citations (2)
Title |
---|
None * |
See also references of WO2011080765A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2011080765A2 (fr) | 2011-07-07 |
CN103596975A (zh) | 2014-02-19 |
WO2011080765A3 (fr) | 2011-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101785290B1 (ko) | 중증 열성 혈소판 감소 증후군 바이러스 감염 진단용 단클론항체, 이를 생산하는 하이브리도마 및 이 단클론항체를 사용하는 중증 열성 혈소판 감소 증후군 바이러스 감염 진단방법 | |
US20240002451A1 (en) | Broad-spectrum peptide antigen of the novel coronavirus sars-cov-2, specific neutralizing antibody and use thereof | |
CN113249333B (zh) | 一种分泌抗呼吸道合胞病毒单克隆抗体的杂交瘤细胞株rsvn4c3 | |
CN108474017B (zh) | 用于检测呼吸道合胞病毒抗原p的单克隆抗体 | |
WO2011080765A2 (fr) | Diabody bivalent humain recombinant contre le virus de la rage et utilisation de celui-ci | |
TW201300421A (zh) | 用於偵測豬繁殖及呼吸道綜合症病毒(prrsv)之試劑及方法 | |
CN109142724B (zh) | 一种用于检测i群禽腺病毒4型抗体的阻断elisa试剂盒及其应用 | |
CN115867350A (zh) | 针对SARS-CoV-2病毒的单域VHH抗体 | |
WO2023026207A1 (fr) | Nouveaux anticorps monoclonaux humains à neutralisation puissante contre le sras-cov-2 (covid-19) | |
WO2022036337A1 (fr) | Compositions et méthodes pour un polypeptide recombinant imitant la protéine nucléocapside (np) du sars-cov-2 | |
Jäckel et al. | Generation and application of monoclonal antibodies against Rift Valley fever virus nucleocapsid protein NP and glycoproteins Gn and Gc | |
KR101865878B1 (ko) | 넙치랩도바이러스에 특이적인 단클론항체 및 이의 용도 | |
KR102086089B1 (ko) | 재조합 n 단백질에 대한 단클론항체를 이용한 아까바네바이러스 블러킹 효소결합면역측정법 | |
CN105504051B (zh) | 狂犬病毒核蛋白单克隆抗体及其应用 | |
KR101080071B1 (ko) | 재조합 n 단백질에 대한 단클론 항체를 이용한 리프트계곡열 경합적 효소결합면역측정법 | |
CN116217716A (zh) | 一种识别柯萨奇病毒a2、a4和a5的单克隆抗体及其应用 | |
KR20240009980A (ko) | 단백질 항원-결합 분자 | |
KR101159806B1 (ko) | 광견병 바이러스를 중화하는 단클론항체 4G31의 scFv유전자 및 이를 발현한 재조합단백질 | |
WO2021198503A1 (fr) | Diagnostic du coronavirus associé au syndrome respiratoire aigu sévère (sras) | |
EP3495386A1 (fr) | Anticorps monoclonaux spécifiques de l'antigène m du virus métapneumovirus humain (hmpv) et leur utilisation dans une méthode diagnostique | |
CN107163108B (zh) | 一种伪狂犬病病毒gE蛋白的抗原表位、抗体的制备及应用 | |
CN116284359B (zh) | 两种靶向新冠病毒s2亚基茎螺旋表位的中和纳米抗体及其潜在应用 | |
CN116987184B (zh) | 新型冠状病毒bq.1.1突变株特异性抗体及其应用 | |
CN116874594B (zh) | 新型冠状病毒突变株xbb.1.5特异性抗体及其应用 | |
CN116769021B (zh) | 一种针对非洲马瘟病毒vp7蛋白的单克隆抗体及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20120703 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20151111 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20171105 |